FDA Nod For Roche’s Columvi Brings Third Anti-CD20 Bispecific To Market

 
• By Alaric DeArment
Roche's Genentech won FDA accelerated approval for Columvi in DLBCL • Source: Shutterstock

More from New Products

More from Scrip